From a theoretical pharmacological standpoint, combining a peptide with putative lipolytic activity (AOD 9604) with a potent triple incretin receptor agonist (retatrutide) could potentially amplify metabolic effects but this is speculative and raises the possibility of compounding adverse effects with no safety data to guide dosing or monitoring
By replenishing B12 levels, it helps restore red blood cell production, supports energy metabolism, and maintains nerve health
Iron typically damages cells in the heart, liver and elsewhere, which can cause significant adverse effects including coma, metabolic acidosis, shock, liver failure, coagulopathy, adult respiratory distress syndrome, long-term organ damage, and even death [63]
In rat models, this effect is associated with elevated levels of the glucose transporter GLUT1 [79]
Research shows that in senescent cells, p53 levels are maintained low through ubiquitination while its pro-apoptotic activity is repressed through nuclear segregation by FOXO4. The peptide's competitive inhibition restores p53 activity by promoting nuclear exclusion, allowing p53 to execute its pro-apoptotic program and eliminate senescent cells through targeted pathway activation
